The National Chinese Pharmaceutical Alliance Collection is 7 points compared to the past

The National Chinese Pharmaceutical Alliance Collection is 7 points compared to the past

Source: Siqi Club/Cao Dianjun

In September 2022, the National Pharmaceutical Alliance was launched. At this point, all categories including chemicals, including chemicals, and biological products have started the national collection.

From the perspective of data, the products included in the National Medicine Alliance Collection are generally products with a market size of over 100 million yuan. From the perspective of competitive manufacturers, the most intense competition in this collection is Xiangdan injection, and more than 50 companies are competing for more than 100 million markets.

Exclusive products have not yet been included in the scope of this collection.

The differences between Chinese medicine and chemicals and chemicals and biological products are different:

The national collection of Chinese medicines lacks 2 provinces, and it is Hunan and Fujian. Due to the trial of Sanming, it will be proven to be the highlight of the reform of the Chinese medicine collection. Hunan is likely to face major reforms because of the recent unsatisfactory incidents of Xiangya Hospital, and it will become a new Sanming.

The National Chinese Pharmaceutical Alliance Procurement is organized by the National Medicine Pharmaceutical Joint Procurement Office, instead of the national organization. The joint procurement office represents medical institutions to carry out concentrated procurement of Chinese medicine and related drugs. The Hubei Provincial Medical Security Bureau undertakes the daily work of the joint procurement office and is responsible for the specific implementation, rather than the Shanghai Medical Central Bidding Procurement Management Office.

The bidding product catalog of 4+7 of the chemical generic drug collection is exactly the same as the product catalog of the alliance collection that was launched later. The second batch of products of the nationwide collection are products that have not yet launched the collection of collection. The product catalog of the Inter -Medicine Alliance of Hubei Medical Pharmaceuticals and the Guangdong Regional Alliance, Shandong and Beijing's product catalogs that have been launched later are not exactly the same. The National Pharmaceutical Alliance's procurement catalog does not include products in Hubei Sino -Pharmaceutical Inter -Pharmaceutical Provincial Association, but it includes individual products that the Guangdong Regional Alliance Collection and Shandong Ji Cai.

There are also chemicals in Sino -Pharmaceuticals in the nationwide collection of chemicals. For example, Ginkgo Da Mono injection and ginkgo leaf extract injections are chemical batch.

Chemical generic drug 4+7, alliance collection, the second batch of bidding rules for national mining, all improved step by step on the basis of the former. The rules of Hubei Medical Pharmaceutical Inter -Medicine Alliance, Guangdong Regional Alliance Collection, Shandong Ji Cai, and Beijing Ji Cai are different. Make improvement. In view of the overlapping products of the National Pharmaceutical Alliance collection, the rules are different, and there may be a situation where medical institutions execute the procurement volume.

The seventh batch of mixed competition manufacturers of chemical generic drugs touched the collection conditions. Two pads of Chinese medicine collection can touch the collection conditions, such as Ginkgo Damo injection, and 3 competitive manufacturers. Ginkgo leaf extract injections are competitive manufacturers.

Zhongcheng Pharmaceutical Collection did not rank from high to low according to the market size. The top products selected and the manufacturer greater than equal to 4 are included in the directory. For example, the same oral medication, although Ansong Niuhuang Pills produced more than 3 billion yuan, but they were not included in the collection.

summary

The Chinese Pharmaceutical National Cai has been launched, and the era of Chinese medicine has arrived. This means that there will be fewer and fewer products with marketing space. In the past, a single Chinese medicine company relying on single products, in addition to facing price wars, must also consider the future transformation direction -whether the diversification can better avoid risks? These are what these companies need to consider.

The seventh bidding products of the chemical country have been sought after by agents. Will the winning products of China Pharmaceutical National Capture be so popular? This is still proven by time.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -